123 related articles for article (PubMed ID: 36580432)
1.
Sinitsina II; Boyarko AV; Temirbulatov II; Sychev DA; Akmalova KA; Sozaeva ZA; Grishina EA; Mirzaev KB; Asoskova AV; Fisenko VP
Drug Metab Pers Ther; 2023 Jun; 38(2):163-168. PubMed ID: 36580432
[TBL] [Abstract][Full Text] [Related]
2. CYP2C9 genetic variants and losartan oxidation in a Turkish population.
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Eur J Clin Pharmacol; 2004 Jul; 60(5):337-42. PubMed ID: 15197523
[TBL] [Abstract][Full Text] [Related]
3. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan.
Yin T; Maekawa K; Kamide K; Saito Y; Hanada H; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Horio T; Takiuchi S; Kawano Y; Minematsu K; Naritomi H; Tomoike H; Sawada J; Miyata T
Hypertens Res; 2008 Aug; 31(8):1549-57. PubMed ID: 18971529
[TBL] [Abstract][Full Text] [Related]
4. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.
Sekino K; Kubota T; Okada Y; Yamada Y; Yamamoto K; Horiuchi R; Kimura K; Iga T
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):589-92. PubMed ID: 14504849
[TBL] [Abstract][Full Text] [Related]
5. [Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].
Pedreros-Rosales C; Jalil Milad R; Lagos Lucero M; Solari Gajardo S
Rev Med Chil; 2019 Dec; 147(12):1527-1534. PubMed ID: 32186616
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.
Donner KM; Hiltunen TP; Suonsyrjä T; Hannila-Handelberg T; Tikkanen I; Antikainen M; Hirvonen A; Kontula K
J Hypertens; 2009 Oct; 27(10):2001-9. PubMed ID: 19593208
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
8. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans.
Allabi AC; Gala JL; Horsmans Y; Babaoglu MO; Bozkurt A; Heusterspreute M; Yasar U
Clin Pharmacol Ther; 2004 Aug; 76(2):113-8. PubMed ID: 15289788
[TBL] [Abstract][Full Text] [Related]
9. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
Bae JW; Choi CI; Kim MJ; Oh DH; Keum SK; Park JI; Kim BH; Bang HK; Oh SG; Kang BS; Park HJ; Kim HD; Ha JH; Shin HJ; Kim YH; Na HS; Chung MW; Jang CG; Lee SY
Acta Pharmacol Sin; 2011 Oct; 32(10):1303-8. PubMed ID: 21841812
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers.
Dorado P; Gallego A; Peñas-LLedó E; Terán E; LLerena A
Pharmacogenomics; 2014 Aug; 15(11):1417-21. PubMed ID: 25303293
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.
Joy MS; Dornbrook-Lavender K; Blaisdell J; Hilliard T; Boyette T; Hu Y; Hogan SL; Candiani C; Falk RJ; Goldstein JA
Eur J Clin Pharmacol; 2009 Sep; 65(9):947-53. PubMed ID: 19669737
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Iwamura A; Fukami T; Hosomi H; Nakajima M; Yokoi T
Drug Metab Dispos; 2011 May; 39(5):838-46. PubMed ID: 21321060
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects.
Huang HX; Wu H; Zhao Y; Zhou T; Ai X; Dong Y; Zhang Y; Lai Y
Xenobiotica; 2021 May; 51(5):616-623. PubMed ID: 33509019
[TBL] [Abstract][Full Text] [Related]
16. Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro.
Wang YH; Pan PP; Dai DP; Wang SH; Geng PW; Cai JP; Hu GX
Xenobiotica; 2014 Mar; 44(3):270-5. PubMed ID: 23844998
[TBL] [Abstract][Full Text] [Related]
17. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.
Dorado P; Beltrán LJ; Machín E; Peñas-Lledó EM; Terán E; Llerena A;
Pharmacogenomics; 2012 Nov; 13(15):1711-7. PubMed ID: 23171336
[TBL] [Abstract][Full Text] [Related]
18. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
19. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
Li Z; Wang G; Wang LS; Zhang W; Tan ZR; Fan L; Chen BL; Li Q; Liu J; Tu JH; Hu DL; Liu ZQ; Zhou HH
Xenobiotica; 2009 Oct; 39(10):788-93. PubMed ID: 19604036
[TBL] [Abstract][Full Text] [Related]
20. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Yasar U; Sain-Guven G; Yardimci Y; Kilicarslan A; Babaoglu MO; Bozkurt A
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):73-7. PubMed ID: 21332946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
